Omeros Corp (OQ:OMER)

Apr 01, 2024 04:02 pm ET
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include:
Mar 27, 2024 08:30 am ET
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Feb 20, 2024 09:00 am ET
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
Feb 01, 2024 09:11 am ET
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.
Nov 09, 2023 04:02 pm ET
Omeros Corporation Reports Third Quarter 2023 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2023, which include:
Nov 06, 2023 08:00 am ET
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Nov 03, 2023 09:05 am ET
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thromboti
Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA. Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The report was authored by an external group of investigators involved in the treatment of these patients with narsoplimab provided under Omeros’ compassionate use program.
Nov 02, 2023 09:05 am ET
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023 in San Diego.
Oct 19, 2023 08:30 am ET
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism.
Oct 16, 2023 07:30 am ET
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today provided an update regarding the interim analysis outcome in ARTEMIS-IGAN, the Company’s Phase 3 trial evaluating narsoplimab for the treatment of immunoglobulin A (IgA) nephropathy.
Aug 09, 2023 08:00 am ET
Omeros Corporation Reports Second Quarter 2023 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2023, which include:
Aug 04, 2023 08:00 am ET
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before the market opens. Omeros management will host a conference call and webcast that same day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Jun 21, 2023 08:30 am ET
Omeros Announces Webcast Details for Annual Meeting of Shareholders
Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023, starting at 10:00 a.m. Pacific Time.
Jun 12, 2023 08:45 am ET
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website. The presentation, which details data from a pre-spe
Jun 01, 2023 11:00 am ET
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder, will be shared at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany. Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.
May 09, 2023 04:02 pm ET
Omeros Corporation Reports First Quarter 2023 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2023, which include:
May 04, 2023 04:06 pm ET
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Apr 25, 2023 09:25 am ET
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder. Statistically significant and clinically meaningful improvements were observed in all measured markers of hemolysis, including hemoglobin (Hgb) and lactate dehydrogenase (LDH). To date, all patients have received only the lowest subcutaneous dose of OMS906 in this mult
Apr 10, 2023 08:45 am ET
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD). The grant is expected to provide $6.69 million over three years and is intended to support both preclinical cocaine interaction studies and a clinical study evaluating the safety and efficacy of OMS527 in patients with CUD.
Mar 13, 2023 04:02 pm ET
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022, which include:
Mar 10, 2023 03:37 pm ET
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.
Mar 07, 2023 09:00 am ET
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Feb 06, 2023 08:50 am ET
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the “Agreement”), pursuant to which Omeros sold its ophthalmology product OMIDRIA® to Rayner in December of 2021.
Dec 23, 2022 09:41 am ET
Thinking about buying stock in AMC Entertainment, TAL Education, Omeros Corp, Acer Therapeutics, or Viking Therapeutics?
NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, TAL, OMER, ACER, and VKTX.
Nov 09, 2022 04:02 pm ET
Omeros Corporation Reports Third Quarter 2022 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022, which include:
Nov 08, 2022 08:30 am ET
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has reached a decision on the company’s formal dispute resolution request appealing the issuance by FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) and the Division of Nonmalignant Hematology (the review division) of a complete response letter (CRL) concerning the biologics license application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Nov 04, 2022 09:00 am ET
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Nov 03, 2022 09:00 am ET
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, which will be held from December 10-13, 2022 in New Orleans. The following abstracts were published today and are now available on the ASH website at
Oct 03, 2022 07:10 am ET
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, an interest in certain royalty payments based on net sales of OMIDRIA (the “Purchased Receivables”). The royalties payable to DRI comprise a portion of the royalties projected to be paid under the terms of the Asset Purchase Agreement (the “Asset Purchase Agreement”), among Omeros, Rayner Surgical Inc. (“Rayner Surgical”) and Rayner Surgical Group Limited, pursuant to which Omeros sold OMIDRIA and related business assets to Rayner
Sep 15, 2022 09:06 am ET
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio [HR]=0.81, with probability [HR
Sep 15, 2022 09:02 am ET
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed in the narsoplimab arm of the I-SPY COVID Trial. The analysis in the randomized patient population, including those who declined treatment after randomization, shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces mortality risk (hazard ratio [HR]=0.81 with probability [HR
Aug 17, 2022 08:40 am ET
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Formal dispute resolution is an official pathway that enables a sponsor to appeal a decision by an FDA division to a hig
Aug 09, 2022 04:02 pm ET
Omeros Corporation Reports Second Quarter 2022 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2022, which include:
Aug 04, 2022 08:30 am ET
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Jul 29, 2022 08:45 am ET
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). OMS906 targets mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D (pro-CFD) to mature CFD.
Jun 15, 2022 08:00 am ET
Omeros Announces Webcast Details for Annual Meeting of Shareholders
Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022, starting at 10:00 a.m. Pacific Time.
May 10, 2022 04:02 pm ET
Omeros Corporation Reports First Quarter 2022 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2022, which include:
May 04, 2022 08:30 am ET
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022, on Tuesday, May 10, 2022, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Apr 20, 2022 08:45 am ET
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved treatment. The manuscript – Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy – will be publishe
Mar 01, 2022 04:02 pm ET
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021, which include:
Feb 24, 2022 07:00 am ET
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesday, March 1, 2022, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Jan 19, 2022 05:52 pm ET
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency’s Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory and legal experts that addresses in detail the points raised by FDA in its CRL for narsoplimab. Omeros concurrently requested a Type A meeting with FDA to
Dec 23, 2021 09:10 am ET
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited. The transaction was completed pursuant to an Asset Purchase Agreement that was
Dec 02, 2021 07:30 am ET
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited. Expected to close on or before December 31, 2021, the transaction includes an upfront payment of $125 million with an additional $200 million in a commercial milestone payment. Omeros will also retain its accounts receivable balance at the closing, which was $34 million at the end of last quarter. Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 bill
Dec 02, 2021 07:30 am ET
Thinking about buying stock in Phunware, Omeros Corp, Humanigen, Spirit AeroSystems, or Arbutus Biopharma?
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, OMER, HGEN, SPR, and ABUS.
Nov 09, 2021 04:02 pm ET
Omeros Corporation Reports Third Quarter 2021 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2021, which include:
Nov 05, 2021 08:40 am ET
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with narsoplimab in this trial was associated with an unprecedented median reduction in proteinuria of 64.4 percent. Now, long-term follow-up (out to 35 months) of these patients shows a markedly slowed rate of decline of estimated glomerular filtration rate (eGFR). Using the same analytical approach adopted by other companies* to determine the impact of proteinuria reduction on long-t
Nov 05, 2021 08:30 am ET
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
The patient, a 21-year-old woman, presented with a rapidly progressive glomerulonephritis. The objective was to stabilize her rapidly deteriorating kidney function to allow for renal transplantation. Her clinical course and response to the MASP-2 inhibitor narsoplimab are detailed in a publication by Selvaskandan et al.1 In brief, kidney biopsy revealed marked vascular damage with significant interstitial fibrosis, tubular atrophy and evidence of complement involvement. Diagnosed with IgA vasculitis, she developed rapidly worsening kidney function with highly elevated creatinine lev
Nov 04, 2021 08:30 am ET
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, November 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Oct 18, 2021 06:30 am ET
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Oct 15, 2021 09:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Oct 11, 2021 03:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Oct 07, 2021 10:30 pm ET
OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) on behalf of Omeros stockholders. Our investigation concerns whether Omeros has violated the federal securities laws and/or engaged in other unlawful business practices.
Oct 07, 2021 12:16 pm ET
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, Oct. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or "the Company") (NASDAQ: OMER) for violations of the securities laws.
Oct 06, 2021 04:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ:
Oct 05, 2021 04:51 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) investors concerning the Company’s possible violations of federal securities laws.
Oct 05, 2021 10:10 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ:
Oct 04, 2021 03:11 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourages Investors With Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ:
Oct 04, 2021 01:11 pm ET
OMER INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation – OMER
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (NASDAQ: OMER) resulting from allegations that Omeros may have issued materially misleading business information to the investing public.
Oct 03, 2021 08:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Oct 01, 2021 08:55 am ET
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA’s ongoing review of the company’s Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. FDA stated that the notification does not reflect a final decision on the information under review.
Aug 09, 2021 04:02 pm ET
Omeros Corporation Reports Second Quarter 2021 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2021, which include:
Aug 03, 2021 08:30 am ET
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Jun 14, 2021 08:30 am ET
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA). The
Jun 10, 2021 08:45 am ET
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced publication of the article “Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission” in
Jun 09, 2021 05:00 pm ET
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m. EDT.
Jun 09, 2021 08:45 am ET
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906. The ongoing trial is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics (PK)
Jun 07, 2021 10:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 02, 2021 10:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
May 28, 2021 08:45 am ET
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. These patients were part of the “second surge” of COVID-19 in Italy. Narsoplimab is the company’s lead in
May 27, 2021 10:08 pm ET
Omeros Corporation Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are...
May 27, 2021 02:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
May 20, 2021 08:45 am ET
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today reported that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microan
May 13, 2021 08:30 am ET
Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress. The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult Patients with High-Risk Transplant-Associated Thrombotic Microangiopathy, will be delivered by Miguel-Angel Perales, M.D., Chief of Adul
May 10, 2021 04:02 pm ET
Omeros Corporation Reports First Quarter 2021 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2021, which include:
May 05, 2021 08:45 am ET
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
May 04, 2021 05:45 am ET
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). The absence of a specific HSCT-TMA diagnosis code has led to underreporting of diagnoses and inaccurate coding, which has complicated reporting of the incidence and outcomes of the disease. This new ICD-10 code, which will be effective October 1, 2021, will for the first time allow clinicians, payers and other
Mar 23, 2021 08:45 am ET
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative. The goal of the trial is to screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.
Mar 01, 2021 04:02 pm ET
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2020, which include:
Feb 25, 2021 09:37 am ET
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Monday, March 1, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Jan 26, 2021 08:45 am ET
Omeros Hires Nadia Dac as Chief Commercial Officer
Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the company’s mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor. A Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy is under Priority Review by U.S. Food and Drug Administration. Ms. Dac will also be responsible for
Jan 19, 2021 08:30 am ET
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The BLA has been granted Priority Review with an FDA action date of July 17, 2021 under the Prescription Drug User Fee Act (PDUFA). FDA also indicated in its filing letter that the Agency is not currently planning to hold an advisory committee meeting to discuss the BLA.
Jan 11, 2021 04:30 pm ET
Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference this year. The presentation is scheduled for Wednesday, January 13, 2021 at 10:50 a.m. EST.
Dec 03, 2020 07:30 am ET
CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers
Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. In its final rule directed to the Medicare outpatient prospective payment system (OPPS) and the ASC payment system for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment under CMS’ policy for non-opioid pain management surgical drugs when used in the ASC setting. This separate payment for
Dec 03, 2020 07:30 am ET
Thinking about buying stock in Pfizer, China Automotive Systems, Omeros Corp, Nio, or FuelCell Energy?
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, CAAS, OMER, NIO, and FCEL.
Nov 18, 2020 09:00 am ET
Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA
Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and has received breakthrough therapy designation and orphan drug designation from FDA for HSCT-TMA.
Nov 09, 2020 04:02 pm ET
Omeros Corporation Reports Third Quarter 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2020, which include:
Nov 05, 2020 07:00 am ET
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Oct 28, 2020 09:00 am ET
Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development
Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today for registered participants only by ROTH Capital Partners entitled COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly. The presentation, which is part of a session on immune modulators to ameliorate COVID-19, is being made by Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer. Dr. Demopulos’ slide presentation from the conference session can be vi
Oct 22, 2020 08:00 am ET
Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved therapy. Narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway and activator of the coagulation cascade, is being studied for the treatment of HSCT-TMA patients at high risk for poor outcomes. Narsoplimab has been awarded Breakthrough Therapy de
Oct 16, 2020 08:30 am ET
Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made by Jason Cummings, Ph.D., Omeros’ Associate Director for Research. Dr. Cummings’ slide presentation can be viewed at
Oct 15, 2020 08:00 am ET
Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be presented in a webcast on Thursday, October 22, 2020 at 8:30 a.m. ET by Miguel Perales, M.D, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, and Alessandro Rambaldi, MD, Professor, Department of Oncology and Hematology-Oncology at the University of Milan and Head of the Hematology and Bone Marrow Transplant Unit at ASST Papa Giovann
Oct 01, 2020 09:00 am ET
Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs
Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The two-year extension of pass-through status provided by Congress through the Consolidated
Sep 11, 2020 07:00 am ET
Omeros to Present at the Cantor Virtual Global Healthcare Conference
Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week. The presentation is scheduled for Tuesday, September 15, 2020 at 11:20 a.m. EDT.
Sep 03, 2020 09:38 am ET
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients
Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The panel session, entitled Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients, was held on September 2, 2020 and included international experts in hematology, oncology and complement science. The panel was moderated by Sara Jane Demy, founder and chief executive officer of Demy-Colton. A replay of the panel can be viewed
Aug 31, 2020 08:00 am ET
Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA
Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway.
Aug 12, 2020 06:30 am ET
Omeros Announces Pricing of Public Offerings
Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock (the “Shares”) at a public offering price of $14.50 per Share for proceeds of approximately $100,050,000, prior to the deduction of underwriting discounts and commissions and estimated offering expenses payable by Omeros (the “Equity Offering”), and $210,000,000 aggregate principal amount of 5.25% convertible senior notes due 2026 (the “2026 Convertible Notes” and such offering, the “Notes Offering”). In addition, Omeros has granted
Aug 10, 2020 04:12 pm ET
Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has commenced concurrent underwritten public offerings of $125,000,000 of shares of its common stock (the “Shares”) and $200,000,000 aggregate principal amount of convertible senior notes due 2026 (the “2026 Convertible Notes”). In addition, Omeros has granted to the underwriters of the offering of Shares (the “Equity Offering”) a 30-day option to purchase up to an additional $18,750,000 of Shares and to the underwriters of the offering of 2026 Convertible Notes (the “Notes Offering”) a 30-day option, solely to cover over-all
Aug 10, 2020 04:01 pm ET
Omeros Corporation Reports Second Quarter 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2020, which include:
Aug 10, 2020 07:30 am ET
Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19. All patients initially required mechanical ventilation, and all recovered and survived with narsoplimab treatment. A manuscript detailing the results of the study has been accepted for publication in the peer-reviewed journal
Jun 12, 2020 08:30 am ET
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 25th Congress of the European Hematology As
Jun 11, 2020 08:45 am ET
Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress
Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of the 25th annual European Hematology Association Congress.
May 14, 2020 09:00 am ET
Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually.
May 11, 2020 04:02 pm ET
Omeros Corporation Reports First Quarter 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2020, which include:
May 05, 2020 07:00 am ET
Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Mar 02, 2020 04:03 pm ET
Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2019, which include:
Mar 02, 2020 04:01 pm ET
Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA
Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and trial enrollment has been closed. Narsoplimab is Omeros’ human monoclonal antibody targeting mannan-binding lectin-associated ser
Feb 24, 2020 07:00 am ET
Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Feb 11, 2020 08:30 am ET
Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors
Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role at Omeros. Mr. Zumwalt brings significant expertise in developing comprehensive business relationships with major banks and financial institutions.
Feb 03, 2020 03:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Dec 18, 2019 08:30 am ET
myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab
myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, today announced a collaboration. The collaboration broadens Omeros’ expanded access program to support availability of Omeros’ novel investigational complement inhibitor narsoplimab in several countries around the world. Narsoplimab is being developed by Omeros as a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and may b
Dec 16, 2019 08:30 am ET
Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology (ESMO) 2019 Immuno-Oncology Congress in Geneva, Switzerland. In addition to previously reported findings, which revealed enhanced anti-tumor immune responses in GPR174-deficient mice and synergism between adenosine receptor antagonists and GPR174 antagonists in promoting interleukin-2 (IL-2) and interferon-γ (IFN-γ) production from human T cells, this presentation included new data from human ex vivo studies demonstrating th
Dec 13, 2019 09:30 am ET
Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares
Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, announced today the full exercise and closing of the sale of 572,518 shares of common stock to the underwriter of its previously announced public offering pursuant to the underwriter’s option under the underwriting agreemen
Dec 10, 2019 08:30 am ET
Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva
Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology 2019 Immuno-Oncology Congress, which is being held December 11-14, 2019 in Geneva, Switzerland.
Dec 05, 2019 09:30 am ET
Omeros Announces Pricing of Upsized Public Offering of Common Stock
Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, announced today the pricing of its registered underwritten public offering of $50.0 million in shares of its common stock at a price to the public of $13.10 per share, before deducting underwriting discounts and other estim
Dec 04, 2019 04:11 pm ET
Omeros Announces Proposed Public Offering of Common Stock
Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced that it has commenced a registered underwritten public offering of its common stock. In addition, Omeros has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of share
Dec 04, 2019 07:00 am ET
Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
Omeros Corporation (Nasdaq: OMER) today announced positive data from its pivotal clinical trial of the company’s novel investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT. These preliminary data were recently provided to FDA as part of the company’s ongoing interactions with the Agency on the narsoplimab Biologics License Application (BLA). All safety and efficacy endpoints – including the composite primary endpoint and the secondary endpoints – are agr
Nov 20, 2019 08:45 am ET
Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online
Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The positively received and well-attended presentation about the company’s cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros’ Director of Immunology. This data can now be accessed on the company’s website at
Nov 19, 2019 08:45 am ET
Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston
Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals.
Nov 12, 2019 04:02 pm ET
Omeros Corporation Reports Third Quarter 2019 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2019.
Nov 11, 2019 05:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Nov 08, 2019 08:30 am ET
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.
Nov 07, 2019 08:30 am ET
Omeros Scientists Win 2019 Prix Galien Research Award
Omeros Corporation (Nasdaq: OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A. Gaitanaris, M.D., Ph.D., chief scientific officer, and Gregory A. Demopulos, M.D., chairman and chief executive officer––have been named as recipients of the 2019 Prix Galien Canada Research Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation, it is referred to as the Nobel Prize of pharmaceutical research.
Nov 06, 2019 08:15 am ET
Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Nov 04, 2019 02:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Nov 04, 2019 07:50 am ET
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of the opioid fentanyl during cataract surgery while also reducing surgical pain were published today in the peer-reviewed journal Clinical Ophthalmology. The article, The Effect of Phenylephrine/Ketorolac Intracameral Solution 1%/0.3% on Pain and Opioid Use During Cataract Surgery, is authored by the study investigator Eric D. Donnenfeld, M.D., Cli
Oct 29, 2019 09:00 am ET
Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission
Omeros Corporation (Nasdaq: OMER) today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has issued a positive opinion for the company’s pediatric investigation plan (PIP) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab, also referred to as OMS721, is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2).
Oct 28, 2019 08:45 am ET
Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) has submitted the first sections of the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a far-too-often deadly complication of stem-cell transplantation.
Oct 01, 2019 08:30 am ET
Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain.
Sep 25, 2019 08:45 am ET
Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria (i.e., high levels of plasma proteins in the urine) and inflammation. The article, published in Frontiers in Immunology and entitled “Absence of the Lectin Activation Pathway of Complement Ameliorates Proteinuria-Induced Renal Injury,” can be accessed online at
Sep 16, 2019 08:45 am ET
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction
Omeros Corporation (Nasdaq: OMER) today announced positive results from its Phase 1 study with the lead compound in its OMS527 program. The OMS527 program is developing phosphodiesterase 7 (PDE7) inhibitors for the treatment of addictions and compulsive disorders as well as movement disorders. The Phase 1 study included single-ascending-dose and multiple-ascending-dose cohorts and was conducted in healthy volunteers.
Sep 11, 2019 08:45 am ET
FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) announced that the United States Food and Drug Administration (FDA) agreed with the company’s proposed schedule for the rolling review of the Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Sep 10, 2019 08:30 am ET
Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174
Omeros Corporation (Nasdaq: OMER) today announced a new approach to cancer immunotherapy that targets inhibition of GPR174, a member of the family of G protein-coupled receptors (GPCRs), which can be combined with and significantly improve the tumor-killing effects of adenosine pathway inhibitors. GPR174-targeting immunotherapy is expected to be applicable to all solid tumors (e.g., breast, lung, pancreas, colon, brain, etc.).
Sep 06, 2019 07:00 am ET
Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next week. The presentation is scheduled for Tuesday, September 10, 2019 at 10:00 a.m. EDT.
Aug 12, 2019 10:30 am ET
Cellulite Treatment Market Projected to Reach $1,438.5 Billion by 2026
PALM BEACH, Florida, Aug. 12, 2019 /PRNewswire/ -- Cellulite has been the bane of many women (and men too) for years, but the market is expected to rise significantly through 2026, industry reports project. One report said that the global cellulite treatment market size was valued at USD $273.94 million in 2018 and is expected to register a CAGR of 8.2% through 2026. Another report added that the global cellulite treatment market was valued at around US$ 619.2 Mn in 2017 and is anticipated to reach US $1,438.5 Mn by 2026, expanding at a CAGR of 10.1% from 2018 to 2026.The second report opine
Aug 09, 2019 08:30 am ET
Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference
Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, August 14, 2019 at 2:30 p.m. EDT.
Aug 08, 2019 04:02 pm ET
Omeros Corporation Reports Second Quarter 2019 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2019.
Aug 05, 2019 04:02 pm ET
Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2019 financial results for the period ended June 30, 2019, on Thursday, August 8, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Jul 31, 2019 08:30 am ET
Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab
Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), also referred to as OMS721. Omeros is preparing to submit a biologics license application (BLA) and a marketing authorization application (MAA) to the U.S. Food and Drug Administration (FDA) and to the European Medicines Agency (EMA), respectively, for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombot
Jul 24, 2019 08:45 am ET
Omeros’ OMIDRIA® Receives Product-Specific J-Code from CMS
Omeros Corporation today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%. OMIDRIA is Omeros’ commercial drug used during cataract surgery to prevent miosis and reduce postoperative pain, improving patient outcomes and safety. The new J-code for OMIDRIA – J1097 – will become effective October 1, 2019.
Jul 11, 2019 08:00 am ET
Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA
Omeros Corporation today announced agreement with the U.S. Food and Drug Administration (FDA) on the response-based primary endpoint for its pivotal trial to support the biologics license application (BLA) for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Jun 05, 2019 08:30 am ET
Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA) currently in preparation for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab, also known as “OMS721,” is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) and is in Phase 3 clinical programs for the treatment of HSCT-TMA, immu
May 15, 2019 07:00 am ET
Omeros to Present at the UBS Global Healthcare Conference
Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at 8:00 a.m. EDT.
May 09, 2019 04:02 pm ET
Omeros Corporation Reports First Quarter 2019 Financial Results
Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2019, which include:
May 07, 2019 09:04 am ET
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
Omeros Corporation (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the incidence of postoperative cystoid macular edema (CME), a sight-threatening complication of cataract surgery. The study results were presented at the joint annual meeting of the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators held in San Diego May 3-7, 2019.
May 06, 2019 06:01 pm ET
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
May 01, 2019 08:30 am ET
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
Omeros Corporation (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American Society of Cataract and Refractive Surgery – American Society of Ophthalmic Administrators Annual Meeting to be held in San Diego May 3-7, 2019. The presentation by Keith A. Walter, M.D., Professor of Ophthalmology at Wake Forest University School of Medicine, is entitled Rate of
Apr 16, 2019 07:20 am ET
Investor Expectations to Drive Momentum within Washington Prime Group, Noble Midstream Partners LP, Omeros, NGL Energy Partners LP, Appian, and WillScot — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington Prime Group Inc. (NYSE:WPG), Noble Midstream Partners LP...
Apr 03, 2019 08:30 am ET
Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
Omeros Corporation (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of gastrointestinal hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) following narsoplimab treatment under a compassionate-use protocol. The case was presented at the 2019 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) held March 24-27 in Frankfurt, Germany. Omeros is reporting the case to ensure broad availability of the information presented. Narsoplimab, Omeros’
Mar 19, 2019 08:30 am ET
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
Omeros Corporation (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation to be held in Frankfurt, Germany on March 24-27, 2019. Sponsored by Omeros, the educational session entitled “How Do I … Diagnose HSCT-TMA” will be held on Tuesday, March 26, at 2:00-3:30 PM local time. There is growing recognition that hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a potentially lethal complication of stem-cell transplants, is
Mar 01, 2019 07:30 am ET
Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2018, which include:
Feb 26, 2019 07:00 am ET
Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.
Feb 22, 2019 07:45 am ET
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Graphic Packaging Holding Company (NYSE:GPK), Vulcan Materials Company...
Feb 20, 2019 08:30 am ET
Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council, in consultation with the World Health Organization’s International Nonproprietary Names (INN) Expert Committee, has selected for the drug the nonproprietary name “narsoplimab.” Narsoplimab is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system,
Feb 14, 2019 08:30 am ET
Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration (FDA), the company has streamlined the required work and further advanced its preparations for its Biologics License Application (BLA) for OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 holds FDA’s breakthrough therapy designation as well as orphan drug designations from FDA and the European Medicines Agency (EMA) for HSCT-TMA. OMS721 is the company’s
Feb 12, 2019 08:30 am ET
Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive Director of the recently established Allen Institute for Immunology and former longtime senior executive at Eli Lilly and Company.
Jan 17, 2019 08:15 am ET
Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the complement system’s lectin pathway. There is no approved treatment for IgA nephropathy.
Jan 14, 2019 07:30 am ET
Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018.
Jan 03, 2019 07:35 am ET
Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of L3 Technologies Inc. (NYSE:LLL), The Goldman Sachs Group, Inc....
Dec 20, 2018 05:03 am ET
Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
Omeros Corporation (Nasdaq: OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for OMS721 in immunoglobulin A (IgA) nephropathy. The committee includes renowned leaders in nephrology and clinical research who will provide clinical guidance to Omeros as it advances its ongoing IgA nephropathy Phase 3 clinical trial ARTEMIS-IGAN.
Dec 11, 2018 07:30 am ET
Omeros Announces Research Collaboration with University of Cambridge
Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway, and to OMS906, Omeros’ lead human monoclonal antibody targeting MASP-3, the key
Dec 06, 2018 08:30 am ET
Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
Omeros Corporation (Nasdaq: OMER) today announced that it has submitted a pediatric investigational plan (PIP) for the use of OMS721 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) to the European Medicines Association (EMA). A pediatric study plan (PSP) is also under development for submission to the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lec
Dec 03, 2018 08:30 am ET
Omeros Announces Additions to Senior Management Team
Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). Their respective responsibilities cover all of Omeros’ programs, with the current primary areas of focus for both being the continued expansion of market success for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% and preparations for the commercialization of OMS721. O
Nov 30, 2018 08:25 am ET
New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omeros Corporation (NASDAQ:OMER), Apple Inc. (NASDAQ:AAPL), Bio-Rad...
Nov 09, 2018 07:00 am ET
Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Securities Act”). Omeros has granted the initial purchasers of the Notes an option to purchase up to an additional $40 million aggregate principal amount of the Notes on the same terms and conditions referenced above.
Nov 08, 2018 04:02 pm ET
Omeros Corporation Reports Third Quarter 2018 Financial Results
Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2018, which include:
Nov 08, 2018 03:26 pm ET
Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023
SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Securities Act"). Omeros also intends to grant the initial purchaser of the Notes a 30-day option to purchase up to an additional $40 million aggregate principal amount of the Notes, for a total potential o
Nov 05, 2018 07:00 am ET
Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.
Oct 23, 2018 08:30 am ET
FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-
Oct 23, 2018 07:30 am ET
New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe's Companies, and Oaktree Specialty Lending — Factors of Influence, Major Initiatives and Sustained Produ
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hecla Mining Company (NYSE:HL), Atlas Air Worldwide Holdings...
Oct 01, 2018 02:15 pm ET
Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy
Omeros Corporation (NASDAQ: OMER) today announced positive data from the company’s ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases. The data are from study patients with immunoglobulin A (IgA) nephropathy, a progressively worsening kidney disease and the most common glomerulonephritis worldwide, responsible for 10 percent of all people on dialysis globally. Patients in this cohort had IgA nephropathy with high risk of progression but none received corticosteroid treatment immediately prior to or during the study – di
Oct 01, 2018 08:45 am ET
Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA®
Omeros Corporation (NASDAQ: OMER) announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company’s cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is effective as of today, October 1, 2018. OMIDRIA, and a small number of other drugs used during procedures performed on Medicare Part B fee-for-service patients, received a two-year extension of pass-through reimbursement status as a result of a bipartisan
Sep 27, 2018 07:00 am ET
Omeros to Present at the 2018 Cantor Global Healthcare Conference
Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Cantor Global Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, October 2, 2018 at 1:05 p.m. EDT.
Sep 07, 2018 07:00 am ET
Omeros to Present at the Morgan Stanley Global Healthcare Conference
Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16th Annual Morgan Stanley Global Healthcare Conference in New York next week. The presentation, which will be a fireside chat format, is scheduled for Thursday, September 13, 2018 at 5:15 p.m. EDT.
Aug 28, 2018 07:55 am ET
Detailed Research: Economic Perspectives on Allegheny Technologies, Ring Energy, Aerohive Networks, Omeros, Adtalem Global Education, and BioPharmX — What Drives Growth in Today's Competitive Landscap
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allegheny Technologies Incorporated (NYSE:ATI), Ring Energy, Inc....
Aug 28, 2018 07:30 am ET
European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT). The adoption by the EC follows a positive opinion for orphan designation of OMS721 in this indication by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2
Aug 10, 2018 07:00 am ET
Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference
Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, August 14, 2018 at 2:30 p.m. EDT.
Aug 09, 2018 04:02 pm ET
Omeros Corporation Reports Second Quarter 2018 Financial Results
Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2018, which include:
Aug 03, 2018 07:00 am ET
Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
Aug 02, 2018 07:00 am ET
Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer
Omeros Corporation (Nasdaq: OMER) today announced that Eckhard Leifke, M.D. has been named Omeros’ Chief Medical Officer and Vice President of Clinical Development. In this role, Dr. Leifke will oversee clinical science & operations, medical affairs and pharmacovigilance. He assumes these corporate responsibilities from J. Steven Whitaker, M.D., J.D., Vice President of Clinical Development, who will now focus primarily on driving the clinical aspects of Omeros’ MASP-2 antibody – OMS721 – toward U.S. and international regulatory approvals in hema
Jul 26, 2018 07:30 am ET
Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire
Omeros Corporation (Nasdaq: OMER) today announced that its patent infringement lawsuit against Sandoz Inc. (Sandoz) concerning Sandoz’s Abbreviated New Drug Application (ANDA), which sought approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Omeros’ cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%, has been dismissed by stipulation of the parties. Omeros agreed to the dismissal because Sandoz amended its ANDA to no longer seek FDA approval to market its
Jul 25, 2018 08:30 am ET
Omeros’ OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell transplantation. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. Three OMS721 Phase 3 clinical programs are progressing across hematopoietic stem cell
Jul 23, 2018 07:15 am ET
Omeros Corporation Initiates Sales of OMIDRIA® in Europe
Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe. OMIDRIA, approved and commercially available in the U.S., is also approved in the European Union (EU) for use in cataract and lens replacement surgery to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. These sales satisfy the “sunset clause” provision in the EU and maintain the ongoing validity of the European marketing authoriz
Jul 17, 2018 07:00 am ET
Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitors of PDE7 have been demonstrated to modulate the brain’s dopamine levels, widely recognized as central to both addictive and compulsive disorders. The trial remains on track to deliver escalating single and multiple doses of the drug.
Jun 27, 2018 09:15 am ET
Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company’s OMS527 program. Omeros discovered the link between PDE7 and addiction, and the company holds broad patents internationally directed to PDE7 inhibitors for the treatment of all addictions and compulsive disorders. The Phase 1 clinical trial will evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic
Jun 26, 2018 07:45 am ET
Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics — Research Highlights Growth, Revenue, and Consolidated Resu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Manitowoc Company, Inc. (NYSE:MTW), Omeros Corporation (NASDAQ:OMER),...
Jun 21, 2018 08:00 am ET
Report: Developing Opportunities within ABIOMED, Avid Technology, Unit, Omeros, Strayer Education, and NeoGenomics — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ABIOMED, Inc. (NASDAQ:ABMD), Avid Technology, Inc. (NASDAQ:AVID), Unit...
May 24, 2018 07:00 am ET
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation against Lupin. The litigation concerned Lupin’s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Omeros’ commercial drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%.
May 10, 2018 04:05 pm ET
Omeros Corporation Reports First Quarter 2018 Financial Results
Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include:
May 07, 2018 10:00 am ET
Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018, on Thursday, May 10, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
Apr 26, 2018 02:15 pm ET
FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patients who have persistent TMA despite modification of immunosuppressive therapy. This is the second breakthrough therapy drug designation for OMS721, which last year received the designation from FDA for the treatment of Immunoglobulin A (IgA) n
Apr 19, 2018 07:35 am ET
Research Report Identifies T. Rowe Price Group, Omeros, Old Dominion Freight Line, Dillard's, BGC Partners, and Rexnord with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of T. Rowe Price Group, Inc. (NASDAQ:TROW),...
Apr 19, 2018 07:00 am ET
Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018. The studies examined the use of OMIDRIA in both routine and complex cataract surgery cases performed in high-volume surgery centers, with and without femto
Apr 13, 2018 09:10 am ET
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018.
Apr 12, 2018 09:10 am ET
OMIDRIA® Added to Veterans Health Administration National Formulary
Omeros Corporation (Nasdaq: OMER) today announced that the Veterans Administration (VA) has added OMIDRIA® (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.S. military veterans. Omeros’ commercial drug OMIDRIA is the first and only FDA-approved product to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain associated with cataract or
Apr 11, 2018 09:15 am ET
Omeros Announces Amendment of Credit Facility
Omeros Corporation (Nasdaq: OMER) today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm. With respect to the twelve-month period beginning on January 1, 2018, the amendment deems Omeros to have met the financial covenants requiring the company to achieve a minimum net revenue or market capitalization amount. The net revenue and market capitalization covenants will continue to apply for 2019 and subsequent years, but the minimum market capitali
Mar 01, 2018 04:02 pm ET
Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results
Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2017, which include:
Feb 26, 2018 09:30 am ET
Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial Results on March 1, 2018
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017, on Thursday, March 1, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.